Cargando…

Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes

AIMS: To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs. METHODS: People with inadequately controlled type 2 diabetes (n = 99) were randomly as...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Cheol-Young, Kang, Jun Goo, Chon, Suk, Noh, Junghyun, Oh, Seung Joon, Lee, Chang Beom, Park, Sung Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948620/
https://www.ncbi.nlm.nih.gov/pubmed/24614911
http://dx.doi.org/10.1371/journal.pone.0087799
_version_ 1782306799888629760
author Park, Cheol-Young
Kang, Jun Goo
Chon, Suk
Noh, Junghyun
Oh, Seung Joon
Lee, Chang Beom
Park, Sung Woo
author_facet Park, Cheol-Young
Kang, Jun Goo
Chon, Suk
Noh, Junghyun
Oh, Seung Joon
Lee, Chang Beom
Park, Sung Woo
author_sort Park, Cheol-Young
collection PubMed
description AIMS: To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs. METHODS: People with inadequately controlled type 2 diabetes (n = 99) were randomly assigned on a 1∶1∶1 basis to receive insulin glargin, with fixed doses of glimepiride, metformin, and glimepiride plus metformin. Outcomes assessed included HbA1c, the changes in fasting glucose levels, body weight, serum lipids values, insulin dose and symptomatic hypoglycemia. RESULTS: After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin, from 8.4±1.0% to 7.7±1.3% (68.8±10.6 mmol/mol to 61.1±14.4 mmol/mol) with insulin glargine plus glimepiride and from 8.7±0.9% to 7.3±0.6% (71.7±9.8 mmol/mol to 56.2±6.7 mmol/mol) with insulin glargine plus glimepirde plus metformin. The decrease in HbA1c was more pronounced with insulin glargine plus glimepiride plus metformin than with insulin glargine plus metformin (0.49% [CI, 0.16% to 0.82%]; P = 0.005) (5.10 mmol/mol [CI, 1.64 to 8.61]; P = 0.005) and insulin glargine plus glimepiride (0.59% [CI, 0.13% to 1.05%]; P = 0.012) (5.87 mmol/mol [CI, 1.10 to 10.64]; P = 0.012) (overall P = 0.02). Weight gain and the risk of hypoglycemia of any type did not significantly differ among the treatment groups. CONCLUSION: The combination therapy of metformin and glimepiride plus glargine insulin resulted in a significant improvement in overall glycemic control as compared with the other combinations. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, NCT00708578. The approval number of Kangbuk Samsung hospital's institutional review board (IRB): C0825.
format Online
Article
Text
id pubmed-3948620
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39486202014-03-13 Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes Park, Cheol-Young Kang, Jun Goo Chon, Suk Noh, Junghyun Oh, Seung Joon Lee, Chang Beom Park, Sung Woo PLoS One Research Article AIMS: To compare the commonly prescribed oral anti-diabetic drug (OAD) combinations to use as an add-on therapy with insulin glargine in patients with uncontrolled type 2 diabetes despite submaximal doses of OADs. METHODS: People with inadequately controlled type 2 diabetes (n = 99) were randomly assigned on a 1∶1∶1 basis to receive insulin glargin, with fixed doses of glimepiride, metformin, and glimepiride plus metformin. Outcomes assessed included HbA1c, the changes in fasting glucose levels, body weight, serum lipids values, insulin dose and symptomatic hypoglycemia. RESULTS: After 24 weeks, HbA1C levels improved from (mean ± SD) 8.5±0.9% to 7.7±0.8% (69.0±10.0 mmol/mol to 60.8±8.6 mmol/mol) with insulin glargine plus metformin, from 8.4±1.0% to 7.7±1.3% (68.8±10.6 mmol/mol to 61.1±14.4 mmol/mol) with insulin glargine plus glimepiride and from 8.7±0.9% to 7.3±0.6% (71.7±9.8 mmol/mol to 56.2±6.7 mmol/mol) with insulin glargine plus glimepirde plus metformin. The decrease in HbA1c was more pronounced with insulin glargine plus glimepiride plus metformin than with insulin glargine plus metformin (0.49% [CI, 0.16% to 0.82%]; P = 0.005) (5.10 mmol/mol [CI, 1.64 to 8.61]; P = 0.005) and insulin glargine plus glimepiride (0.59% [CI, 0.13% to 1.05%]; P = 0.012) (5.87 mmol/mol [CI, 1.10 to 10.64]; P = 0.012) (overall P = 0.02). Weight gain and the risk of hypoglycemia of any type did not significantly differ among the treatment groups. CONCLUSION: The combination therapy of metformin and glimepiride plus glargine insulin resulted in a significant improvement in overall glycemic control as compared with the other combinations. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov, NCT00708578. The approval number of Kangbuk Samsung hospital's institutional review board (IRB): C0825. Public Library of Science 2014-03-10 /pmc/articles/PMC3948620/ /pubmed/24614911 http://dx.doi.org/10.1371/journal.pone.0087799 Text en © 2014 Park et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Park, Cheol-Young
Kang, Jun Goo
Chon, Suk
Noh, Junghyun
Oh, Seung Joon
Lee, Chang Beom
Park, Sung Woo
Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title_full Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title_fullStr Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title_full_unstemmed Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title_short Comparison between the Therapeutic Effect of Metformin, Glimepiride and Their Combination as an Add-On Treatment to Insulin Glargine in Uncontrolled Patients with Type 2 Diabetes
title_sort comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948620/
https://www.ncbi.nlm.nih.gov/pubmed/24614911
http://dx.doi.org/10.1371/journal.pone.0087799
work_keys_str_mv AT parkcheolyoung comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT kangjungoo comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT chonsuk comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT nohjunghyun comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT ohseungjoon comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT leechangbeom comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes
AT parksungwoo comparisonbetweenthetherapeuticeffectofmetforminglimepirideandtheircombinationasanaddontreatmenttoinsulinglargineinuncontrolledpatientswithtype2diabetes